Evidence map›Paper›PMID 24887184›Full record

ArticlePloS one2014

Characterization of metastasis formation and virotherapy in the human C33A cervical cancer model.

Ulrike Donat, Juliane Rother, Simon Schäfer, Michael Hess, Barbara Härtl, Christina Kober, Johanna Langbein-Laugwitz, Jochen Stritzker, Nanhai G Chen, Richard J Aguilar and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ulrike DonatInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Juliane RotherInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Simon SchäferInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Michael HessInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Barbara HärtlInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany; Genelux GmbH, Bernried, Germany.
Christina KoberInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Johanna Langbein-LaugwitzInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Jochen StritzkerInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany; Genelux Corporation, San Diego Science Center, San Diego, California, United States of America.
Nanhai G ChenGenelux Corporation, San Diego Science Center, San Diego, California, United States of America; Department of Radiation Medicine and Applied Sciences, Rebecca & John Moores Comprehensive Cancer Center, University of California, San Diego, California, United States of America.
Richard J AguilarGenelux Corporation, San Diego Science Center, San Diego, California, United States of America.
Stephanie WeibelInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany.
Aladar A SzalayInstitute of Biochemistry, University of Wuerzburg, Wuerzburg, Germany; Genelux Corporation, San Diego Science Center, San Diego, California, United States of America; Department of Radiation Medicine and Applied Sciences, Rebecca & John Moores Comprehensive Cancer Center, University of California, San Diego, California, United States of America; Genelux GmbH, Bernried, Germany; Rudolph Virchow Center for Experimental Biomedicine and Institute for Molecular Infection Biology, University of Wuerzburg, Wuerzburg, Germany.
University of Würzburg · DEGenelux (United States) · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 90% of cancer mortalities are due to cancer that has metastasized. Therefore, it is crucial to intensify research on metastasis formation and therapy. Here, we describe for the first time the metastasizing ability of the human cervical cancer cell line C33A in athymic nude mice after subcutaneous implantation of tumor cells. In this model, we demonstrated a steady progression of lumbar and renal lymph node metastases during tumor development. Besides predominantly occurring lymphatic metastases, we visualized the formation of hematogenous metastases utilizing red fluorescent protein (RFP) expressing C33A-RFP cells. RFP positive cancer cells were found migrating in blood vessels and forming micrometastases in lungs of tumor-bearing mice. Next, we set out to analyze the influence of oncolytic virotherapy in the C33A-RFP model and demonstrated an efficient virus-mediated reduction of tumor size and metastatic burden. These results suggest the C33A-RFP cervical cancer model as a new platform to analyze cancer metastases as well as to test novel treatment options to combat metastases.

Indexed as

Models, BiologicalNeoplasm MetastasisOncolytic VirotherapyAnimalsCell CycleCell Line, TumorFemaleHumansLymphatic MetastasisMiceMicroscopy, FluorescenceUterine Cervical Neoplasms

Identifiers

PMID24887184
PMCPMC4041767
OpenAlexW2033603857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.